Intellia Therapeutics has said it will reduce its ... its resources behind two priority drug candidates. The specialist in CRISPR-based gene editing – co-founded by Nobel Prize winner Jennifer ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization. Read more about EDIT and NTLA stocks here.

All You Need to Know About Intellia Therapeutics Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered ...

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.

Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...

Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of ...

It has been many moons since I last held a position in Intellia Therapeutics ... their staff and halt the development of one of their CRISPR candidates, NTLA-3001 for alpha-1 antitrypsin ...

Intellia Therapeutics is starting off 2025 with a ... to kick off its J.P. Morgan Healthcare Conference news cycle. The CRISPR company, once at the cutting edge of new life sciences research ...

NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.

CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from Chardan Capital analyst Geulah Livshits ...

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats ...